Lantheus Holdings Inc

0L8

Company Profile

  • Business description

    Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

  • Contact

    201 Burlington Road
    South Building
    BedfordMA01730
    USA

    T: +1 978 671-8001

    E: [email protected]

    https://www.lantheus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    808

Stocks News & Analysis

stocks

What next for the largest company on the ASX?

After a historic rally in 2024, what lies ahead for this overvalued banking titan?
stocks

Ask the analyst: Are IDP Education's woes temporary?

The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks

Is it time to buy the Magnificent Seven?

After the recent selloff, the bull market’s most in-demand stocks look much cheaper.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,013.3046.700.59%
CAC 408,030.6892.471.16%
DAX 4022,952.32385.181.71%
Dow JONES (US)40,813.57537.36-1.30%
FTSE 1008,598.9956.430.66%
HKSE23,959.98497.332.12%
NASDAQ17,303.01345.44-1.96%
Nikkei 22537,053.10263.070.72%
NZX 50 Index12,266.2557.200.47%
S&P 5005,521.5277.78-1.39%
S&P/ASX 2007,789.7040.600.52%
SSE Composite Index3,419.5660.831.81%

Market Movers